Download PDF
Semin Thromb Hemost 2002; 28(1): 29-38
DOI: 10.1055/s-2002-20562
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Effect of Antihemostatic Agents on Experimental Tumor Dissemination

John L. Francis, Ali Amirkhosravi
  • Clinical and Research Laboratories, Florida Hospital Cancer Institute, Orlando, Florida
Further Information

Publication History

Publication Date:
05 March 2002 (online)

   Permissions and Reprints

ABSTRACT

There is now considerable evidence that the blood coagulation system plays an important role in the biology of malignant tumors. This evidence has been derived from a combination of clinical, biochemical, histological, and pharmacological observations that point to the possibility of favorably affecting the course of malignant disease with agents that interfere with blood coagulation pathways. For a number of years our laboratory has used experimental models of blood-borne metastasis to study the events that follow the introduction of procoagulant-bearing tumor cells into the circulating blood. This article summarizes our experience with these models, which suggests that intravascular coagulation is a necessary prelude to lung tumor formation and that interruption of coagulation pathways in various ways may be an effective antimetastatic strategy. We have shown that anticoagulation with commonly used agents such as unfractionated heparin and warfarin (Coumadin) prevent tumor formation by limiting the ability of tumor cells to be retained in the pulmonary microvasculature. Binding of fibrin-coated tumor cells to activated platelets is essential for this retention and, therefore, treatment with potent antiplatelet agents such as abciximab is also effective. The predominant tumor procoagulant is tissue factor (TF), and direct targeting of this protein with concanavalin A, monoclonal antibodies, and tissue factor pathway inhibitor (TFPI) has provided compelling evidence that TF is an important determinant of tumor seeding in these experimental models. Collectively, our data provide strong support for the concept that some form of anticoagulant therapy would be a useful adjunct to existing cancer treatments.

KEYWORD

Cancer - metastasis - tissue factor - anticoagulants - Coumadin - heparin - tissue factor pathway inhibitor - treatments

REFERENCES

  • 1 Hillen H F. Thrombosis in cancer patients.  Ann Oncol . 2000;  11(Suppl 3) 273-276
    Search in Google Scholar
  • 2 Bick R L. Coagulation abnormalities in malignancy: a review.  Semin Thromb Hemost . 1992;  18 353-372
    Thieme ConnectPubMedSearch in Google Scholar
  • 3 Prandoni P, Lensing A WA, Büller H R. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer.  N Engl J Med . 1992;  327 1128-1133
    CrossrefPubMedSearch in Google Scholar
  • 4 Levine M. Treatment of thrombotic disorders in cancer patients.  Haemostasis . 1997;  27 38-43
    PubMedSearch in Google Scholar
  • 5 Kakkar A K, Williamson R C. Thromboprophylaxis in the cancer patient.  Haemostasis . 1998;  28(Suppl 3) 61-65
    CrossrefPubMedSearch in Google Scholar
  • 6 Sun N CJ, McAfee W M, Hum G J, Weiner J M. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part 1. Coagulation studies.  Am J Clin Pathol . 1979;  71 10-16
    PubMedSearch in Google Scholar
  • 7 Francis J L, Francis D A, Gunathilagan G J. Assessment of hypercoagulability in patients with cancer using the Sonoclot analyzer and thromboelastography.  Thromb Res . 1994;  74 335-346
    CrossrefPubMedSearch in Google Scholar
  • 8 Rickles F R, Edwards R L, Barb C, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation and tumor growth.  Cancer . 1983;  51 301-307
    PubMedSearch in Google Scholar
  • 9 Seitz R, Rappe N, Kraus M. Activation of coagulation and fibrinolysis in patients with lung cancer-relation to tumour stage and prognosis.  Blood Coagul Fibrinolysis . 1993;  4 249-254
    CrossrefPubMedSearch in Google Scholar
  • 10 Duncan A, Howard T, League A. Markers of coagulation and hemostasis activation (MOCHA) as indicators of unsuspected malignancy.  Thromb Haemost . 1997;  85(Suppl) 123-123 Abst
    PubMedSearch in Google Scholar
  • 11 Brown J M. A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases.  Cancer Res . 1973;  33 1217-1224
    PubMedSearch in Google Scholar
  • 12 Poggi A, Mussoni L, Kornblihtt L. Warfarin enantiomers, anticoagulation and experimental tumour metastasis.  Lancet . 1978;  1 163-164
    PubMedSearch in Google Scholar
  • 13 Donati M B, Roncaglioni M C, Falanga A, Casali B, Semeraro N. Vitamin K-dependent procoagulant in cancer cells: a potential target for the anti-metastatic effect of warfarin.  Haemostasis . 1986;  16 288-294
    PubMedSearch in Google Scholar
  • 14 Goeting N LM, Trotter G A, Taylor I. Effect of warfarin on formation and growth of pre-neoplastic lesions in chemically-induced colorectal cancer in the rat.  Br J Surg . 1986;  73 487-489
    PubMedSearch in Google Scholar
  • 15 McCulloch P, George W D. Warfarin inhibition of metastasis: the role of anticoagulation.  Br J Surg . 1987;  74 879-883
    PubMedSearch in Google Scholar
  • 16 McCulloch P, George W D. Warfarin inhibits metastasis of Mtln3 rat mammary carcinoma without affecting primary tumour growth.  Br J Cancer . 1989;  59 179-183
    PubMedSearch in Google Scholar
  • 17 Thornes R D. Fibrin and cancer.  Br Med J . 1972;  1 110-111
    PubMedSearch in Google Scholar
  • 18 Zacharski L R. Small cell carcinoma of the lung: interaction with the blood coagulation mechanism and treatment with anticoagulants.  Onkologie . 1987;  10 264-270
    PubMedSearch in Google Scholar
  • 19 Daly L. The first international urokinase/warfarin trial in colorectal cancer.  Clin Exp Metastasis . 1991;  9 3-11
    CrossrefPubMedSearch in Google Scholar
  • 20 Carpi A, Sagripanti A, Poddighe R, Gherarducci G, Nicolini A. Cancer incidence and mortality in patients with heart disease. Effect of oral anticoagulant therapy.  Am J Clin Oncol . 1995;  18 15-18
    PubMedSearch in Google Scholar
  • 21 Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial.  N Engl J Med . 2000;  342 1953-1958
    CrossrefPubMedSearch in Google Scholar
  • 22 Kakkar A K, Williamson R C. Prevention of venous thromboembolism in cancer using low-molecular-weight heparins.  Haemostasis . 1997;  27(Suppl 1) 32-37
    PubMedSearch in Google Scholar
  • 23 Ornstein D L, Zacharski L R. The use of heparin for treating human malignancies.  Haemostasis . 1999;  29(Suppl S1) 48-60
    CrossrefPubMedSearch in Google Scholar
  • 24 Von Tempelhoff F G, Harenberg J, Niemann F. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial.  Int J Oncol . 2000;  16 815-824
    PubMedSearch in Google Scholar
  • 25 Engelberg H. Actions of heparin that may affect the malignant process.  Cancer . 1999;  85 257-272
    CrossrefPubMedSearch in Google Scholar
  • 26 Zacharski L R, Memoli V A, Costantini V, Wojtukiewicz M Z, Ornstein D L. Clotting factors in tumour tissue: implications for cancer therapy.  Blood Coagul Fibrinolysis . 1990;  1 71-78
    PubMedSearch in Google Scholar
  • 27 Carmeliet P, Collen D. Molecular analysis of blood vessel formation and disease.  Am J Physiol . 1997;  273 H2091-H2104
    PubMedSearch in Google Scholar
  • 28 O'Brien D P. The molecular biology and biochemistry of tissue factor.  Baillieres Clin Haematol . 1989;  2 801-820
    PubMedSearch in Google Scholar
  • 29 Petersen L C, Freskgard P, Ezban M. Tissue factor-dependent factor VIIa signaling.  Trends Cardiovasc Med . 2000;  10 47-52
    CrossrefPubMedSearch in Google Scholar
  • 30 Carmeliet P, Mackman N, Moons L. Role of tissue factor in embryonic blood vessel development.  Nature . 1996;  383 73-75
    CrossrefPubMedSearch in Google Scholar
  • 31 Zhang Y, Deng Y, Luther T. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice.  J Clin Invest . 1994;  94 1320-1327
    Search in Google Scholar
  • 32 Connolly D T. Vascular permeability factor: a unique regulator of blood vessel function.  J Cell Biochem . 1991;  47 219-223
    CrossrefPubMedSearch in Google Scholar
  • 33 Shoji M, Abe K, Dillehay D. Tissue factor (TF) regulates the expression of vascular endothelial growth factor (VEGF) in vitro and angiogenesis in vivo in human breast cancer and melanoma.  Blood . 1996;  88 514a-514a Abst
    PubMedSearch in Google Scholar
  • 34 Carmeliet P, Moons L, Dewerchin M. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system.  Ann NY Acad Sci . 1997;  811 191-206
    PubMedSearch in Google Scholar
  • 35 Koomägi R, Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis.  Int J Cancer . 1998;  79 19-22
    CrossrefPubMedSearch in Google Scholar
  • 36 Nakagawa K, Zhang Y, Tsuji H. The angiogenic effect of tissue factor on tumors and wounds.  Semin Thromb Hemost . 1998;  24 207-210
    PubMedSearch in Google Scholar
  • 37 Ollivier V, Bentolila S, Chabbat J, Hakim J, de Prost D. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII.  Blood . 1998;  91 2698-2703
    PubMedSearch in Google Scholar
  • 38 Shoji M, Hancock W W, Abe K. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer.  Am J Pathol . 1998;  152 399-411
    PubMedSearch in Google Scholar
  • 39 Zucker S, Mirza H, Conner C E. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation.  Int J Cancer . 1998;  75 780-786
    CrossrefPubMedSearch in Google Scholar
  • 40 Mechtcheriakova D, Wlachos A, Holzmüller H, Binder B R, Hofer E. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1.  Blood . 1999;  93 3811-3823
    PubMedSearch in Google Scholar
  • 41 Rickles F R, Shoji M, Abe K. The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer.  Int J Hematol . 2001;  73 145-150
    CrossrefPubMedSearch in Google Scholar
  • 42 Shweioki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.  Nature . 1992;  359 843-845
    CrossrefPubMedSearch in Google Scholar
  • 43 Amirkhosravi A, Meyer T, Warnes G. Pentoxifylline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelial growth factor.  Thromb Haemost . 1998;  80 598-602
    PubMedSearch in Google Scholar
  • 44 Greeno E W, Bach R R, Moldow C F. Apoptosis is associated with increased cell surface tissue factor procoagulant activity.  Lab Invest . 1996;  75 281-289
    PubMedSearch in Google Scholar
  • 45 Dover R, Goeting N L, Taylor I, Roath O S, Francis J L. Factor X-activating activity in patients with colorectal carcinoma.  Br J Surg . 1987;  74 1122-1124
    PubMedSearch in Google Scholar
  • 46 Rickles F R, Hancock W W, Edwards R L, Zacharski L R. Antimetastatic agents. I. Role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment.  Semin Thromb Hemost . 1988;  14 88-94
    PubMedSearch in Google Scholar
  • 47 Amirkhosravi M, Francis J L. Procoagulant effects of the MC28 fibrosarcoma cell line in vitro and in vivo.  Br J Haematol . 1993;  85 736-744
    PubMedSearch in Google Scholar
  • 48 Edwards R L, Silver J, Rickles F R. Human tumor procoagulants: Registry of the Subcommittee of Haemostasis of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis.  Thromb Haemost . 1993;  69 205-213
    PubMedSearch in Google Scholar
  • 49 Adamson A S, Luckert P, Pollard M. Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer.  Br J Cancer . 1994;  69 286-290
    PubMedSearch in Google Scholar
  • 50 Amirkhosravi M, Francis J L. Coagulation activation by MC28 fibrosarcoma cells facilitates lung tumor formation.  Thromb Haemost . 1995;  73 59-65
    Search in Google Scholar
  • 51 Francis J L, Carty N, Amirkhosravi M. The effect of warfarin and factor VII on tissue procoagulant activity and pulmonary seeding.  Br J Cancer . 1992;  65 329-334
    PubMedSearch in Google Scholar
  • 52 Chew E-C, Wallace A C. Demonstration of fibrin in early stages of experimental metastases.  Cancer Res . 1976;  36 1904-1909
    PubMedSearch in Google Scholar
  • 53 Crissman J D, Hatfield J, Shaldenbrand M, Sloane B F, Honn K V. Arrest and extravasation of B16 amelanotic melanoma in murine lungs: a light and electron microscope study.  Lab Invest . 1985;  53 470-478
    PubMedSearch in Google Scholar
  • 54 Biggerstaff J P, Seth N, Amirkhosravi A. Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis.  Clin Exp Metastasis . 1999;  17 723-730
    CrossrefPubMedSearch in Google Scholar
  • 55 Borsig L, Wong R, Feramisco J. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis.  Proc Natl Acad Sci USA . 2001;  98 3352-3357
    CrossrefPubMedSearch in Google Scholar
  • 56 Gasic G J, Gasic T B, Stewart C C. Antimetastatic effects associated with platelet reduction.  Proc Natl Acad Sci USA . 1968;  61 46-52
    PubMedSearch in Google Scholar
  • 57 Gasic G J, Gasic T B, Murphy S. Anti-metastatic effect of aspirin.  Lancet . 1972;  2 934
    PubMedSearch in Google Scholar
  • 58 Tzanakakis G N, Agarwal K C, Vezeridis M P. Prevention of human pancreatic cancer cell-induced hepatic metastasis in nude mice by dipyridamole and its analog RA-233.  Cancer . 1993;  71 2466-2471
    PubMedSearch in Google Scholar
  • 59 Amirkhosravi A, Amaya M, Siddiqui F A. Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis.  Platelets . 1999;  10 285-292
    CrossrefPubMedSearch in Google Scholar
  • 60 Verheul H MW, Hoekman K, Luykx-de B S. Platelet: transporter of vascular endothelial growth factor.  Clin Cancer Res . 1997;  3 2187-2190
    PubMedSearch in Google Scholar
  • 61 Verheul H M, Pinedo H M. Tumor growth: a putative role for platelets?.  Oncologist . 1998;  3 II
    PubMedSearch in Google Scholar
  • 62 Wartiovaara U, Salven P, Mikkola H. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation.  Thromb Haemost . 1998;  80 171-175
    PubMedSearch in Google Scholar
  • 63 Banks R E, Forbes M A, Kinsey S E. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology.  Br J Cancer . 1998;  77 956-964
    CrossrefPubMedSearch in Google Scholar
  • 64 Zacharski L R, Rosenstein R, Phillips P G. Concanavalin A inhibition of tissue factor (thromboplastin) activity.  Blood . 1974;  44 783-787
    PubMedSearch in Google Scholar
  • 65 Kirchhofer D, Banner D W. Molecular and structural advances in tissue factor-dependent coagulation.  Trends Cardiovasc Med . 1997;  7 316-324
    CrossrefPubMedSearch in Google Scholar
  • 66 Broze Jr J G. Tissue factor pathway inhibitor and the revised theory of coagulation.  Annu Rev Med . 1995;  46 103-112
    CrossrefPubMedSearch in Google Scholar
  • 67 Lindahl A K, Sandset P M, Abildgaard U. The present status of tissue factor pathway inhibitor.  Blood Coagul Fibrinolysis . 1992;  3 439-449
    PubMedSearch in Google Scholar
  • 68 Ostergaard P, Nordfang O, Petersen L C, Valentin S, Kristensen H. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins-biochemical considerations.  Haemostasis . 1993;  23 107-111
    PubMedSearch in Google Scholar
  • 69 Lupu C, Poulsen E, Roquefeuil S. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture.  Arterioscler Thromb Vasc Biol . 1999;  19 2251-2262
    Search in Google Scholar
  • 70 Werling R W, Zacharski L R, Kisiel W. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues.  Thromb Haemost . 1993;  69 366-369
    Search in Google Scholar
  • 71 Rapp J H, Pan X M, Ghermay A. A blinded trial of local recombinant tissue factor pathway inhibitor versus either local or systemic heparin in a vein bypass model.  J Vasc Surg . 1997;  25 726-729
    PubMedSearch in Google Scholar
  • 72 St Pierre J, Yang L Y, Tamirisa K. Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs.  Arterioscler Thromb Vasc Biol . 1999;  19 2263-2268
    Search in Google Scholar
  • 73 Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis.  Crit Care Med . 2000;  28 S31-S33
    Search in Google Scholar
  • 74 Lincoff A M. First clinical investigation of a tissue-factor inhibitor administered during percutaneous coronary revascularization: a randomized, double-blinded, dose-escalation trial-Assessing safety and efficacy of FFR-FVIIa in percutaneous transluminal coronary angioplasty (ASIS) trial.  J Am Coll Cardiol . 2000;  136 312-313
    PubMedSearch in Google Scholar
  • 75 Nishida T, Ueno H, Atsuchi N. Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced recurrent thrombosis in the injured carotid artery of the rabbit.  Circ Res . 1999;  84 1446-1452
    Search in Google Scholar
  • 76 Zoldhelyi P, Chen Z Q, Shelat H S, McNatt J M, Willerson J T. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries.  Proc Natl Acad Sci USA . 2001;  98 4078-4083
    Search in Google Scholar
  • 77 Donnelly K M, Bromberg M E, Milstone A. Ancylostoma caninum anticoagulant peptide blocks metastasis in vivo and inhibits factor Xa binding to melanoma cells in vitro.  Thromb Haemost . 1998;  79 1041-1047
    Search in Google Scholar
  • 78 Fischer E G, Ruf W, Mueller B M. Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells.  Cancer Res . 1995;  55 1629-1632
    PubMedSearch in Google Scholar
  • 79 Esumi N, Fan D, Fidler I J. Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor.  Cancer Res . 1991;  51 4549-4556
    PubMedSearch in Google Scholar
  • 80 Camerer E, Huang W, Coughlin S R. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa.  Proc Natl Acad Sci USA . 2000;  97 5255-5260
    CrossrefPubMedSearch in Google Scholar
  • 81 Valentine K A, Hull R D, Pineo G F. Low-molecular-weight heparin therapy and mortality.  Semin Thromb Hemost . 1997;  23 173-178
    PubMedSearch in Google Scholar
  • 82 Zacharski L R, Ornstein D L, Mamourian A C. Low-molecular-weight heparin and cancer.  Semin Thromb Hemost . 2000;  26(Suppl 1) 69-77
    Search in Google Scholar